Showing 7621-7630 of 8649 results for "".
- Lilly’s Bamlanivimab Cuts Risk of COVID-19 By Up to 80% at Nursing Homeshttps://modernod.com/news/lillys-bamlanivimab-cuts-risk-of-covid-19-by-up-to-80-at-nursing-homes/2478788/Eli Lilly announced Thursday that in a phase 3 study, bamlanivimab was shown to significantly reduce the risk of contracting symptomatic COVID-19 among residents and staff of long-term care facilities. The findings from the BLAZE-2 COVID-19 prevention trial suggest the risk was decreased by up to
- Keeler Partners With Merakris Therapeutics, Developer of Biological Barrier Grafthttps://modernod.com/news/keeler-patners-with-merakris-therapeutics-developer-of-biological-barrier-graft/2478785/Keeler has announced its partnership with Merakris Therapeutics, which is developing commercially scalable biotherapeutic technologies derived from stem cells that promote homeostasis in damaged tissue. Terms of the deal were not disclosed. “We are excited. This partnership accelera
- Ocular Therapeutix Presents Interim Topline Data from the Phase 1 Clinical Trial of OTX-TIC in Patients With Glaucomahttps://modernod.com/news/ocular-therapeutix-presents-interim-topline-data-from-the-phase-1-clinical-trial-of-otx-tic-in-patients-with-glaucoma/2478784/Ocular Therapeutix announced plans to present data on OTX-TIC, a travoprost intracameral implant for the treatment of patients with primary open angle glaucoma or ocular hypertension, at the Glaucoma 360 New Horizons Forum being held virtually on January 30. As part of the event, Michael Goldstei
- Rayner Enters Canadian Ophthalmology Markethttps://modernod.com/news/rayner-enters-canadian-ophthalmology-market/2478773/Following the recent approval of incorporation, Rayner announced that is will now be offering the Rayner portfolio of IOLs and injectors directly to Canadian surgeons. The entry into the Canadian market will be led by Wade Allen, Director: Americas, Rayner Surgical Corp. The RayOne Aspheri
- Bausch + Lomb Completes Enrollment Of First Phase 3 Study For NOV03 (Perfluorohexyloctane)https://modernod.com/news/bausch-lomb-completes-enrollment-of-first-phase-3-study-for-nov03-perfluorohexyloctane/2478770/Bausch + Lomb and Novaliq announced the first of two phase 3 studies evaluating NOV03 as a first-in-class investigational drug with a novel mechanism of action to treat the signs and symptoms of dry eye disease (DED) associated with Meibomian gland dysfunction (MGD) has been completely enrolled w
- Smart Contact Lens Targets Vision Improvement for Those With Impairmentshttps://modernod.com/news/smart-contact-lens-targets-vision-improvement-for-those-with-impairments/2478766/A contact lens that operates like a smartphone in the eye was the breakout but not-yet-ready-for-prime-time health tech at Consumer Electronics Show (CES) this year, according to a Medscape report. The device wields computing and imaging p
- Study: Implandata’s Eyemate System Protects Glaucoma Patients–Even During Lockdownhttps://modernod.com/news/study-implandatas-eyemate-system-protects-glaucoma-patients-even-during-lockdown/2478767/Patients with glaucoma are at high risk of losing their eyesight if their disease progresses undetected and essential therapy adjustments are delayed. On the other hand, these typically elderly, vulnerable individuals are often hampered in seeing their doctor for office visits, particularly durin
- Biden Picks Former FDA Commissioner David Kessler to Lead Operation Warp Speedhttps://modernod.com/news/biden-picks-former-fda-commissioner-david-kessler-to-lead-operation-warp-speed/2478768/US President-elect Joe Biden announced a number of appointments to the incoming team handling the response to the COVID-19 pandemic, including naming David Kessler as chief science officer. Mr. Kessler, who served as FDA commissioner between 1990 and 1997, will reportedly share oversight of Opera
- James Reid Named CEO of Versant Healthhttps://modernod.com/news/james-reid-named-ceo-of-versant-health/2478762/MetLife announced that James Reid has been named CEO of Versant Health, a managed vision care company and wholly owned subsidiary of MetLife. The appointment is effective April 1. “James brings extensive and varied experience in the Group Benefits market to Versant Health,” Todd Katz, chai
- Printable Chart Suitable for Stay-at-Home Visual Evaluationhttps://modernod.com/news/printable-chart-suitable-for-stay-at-home-visual-evaluation/2478763/A chart that can be downloaded or printed and mailed to patients appears effective in helping determine visual acuity via telephone assessments, according to researchers in the UK, Reuters reported. “We are excited to be deve